Browse by author
Lookup NU author(s): Dr Rajiv Das
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2025 Massachusetts Medical Society.Background Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke. Methods We conducted a randomized, controlled trial across 33 centers in the United Kingdom. We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was stroke within 72 hours after TAVI or before discharge from the hospital (if discharge occurred sooner). Results A total of 3815 participants were assigned to the CEP group and 3820 to the control group. A primary-outcome event occurred in 81 of 3795 participants (2.1%) in the CEP group and in 82 of 3799 participants (2.2%) in the control group (difference, -0.02 percentage points; 95% confidence interval, -0.68 to 0.63; P=0.94). Disabling stroke occurred in 47 participants (1.2%) in the CEP group and in 53 (1.4%) in the control group. Death occurred in 29 participants (0.8%) in the CEP group and in 26 (0.7%) in the control group. Overall access-site complications appeared to be similar in the two groups (8.1% in the CEP group and 7.7% in the control group). A total of 24 serious adverse events occurred in 22 of 3798 participants (0.6%) in the CEP group, and 13 serious adverse events occurred in 13 of 3803 participants (0.3%) in the control group. Conclusions Among participants undergoing TAVI, routine use of CEP did not decrease the incidence of stroke within 72 hours.
Author(s): Kharbanda RK, Kennedy J, Jamal Z, Dodd M, Evans R, Bal KK, Perkins AD, Blackman DJ, Hildick-Smith D, Banning AP, Baumbach A, Ludman P, Palmer S, Stables RH, Henderson R, Appleby C, Cotton J, Curzen N, Ozkor M, Byrne J, Aggarwal R, Das R, Doshi S, Watkins S, Muir DF, Anderson R, Chowdhary S, Varcoe R, Dorman S, Firoozi S, Chelliah R, Owens C, Redwood S, Prendergast B, Iqbal J, Ratib K, Dospinescu C, Suresh V, Cruden N, Rajathurai T, Malik IS, Wiper A, Costopoulos C, Khurana A, Banning A, Clayton T
Publication type: Article
Publication status: Published
Journal: New England Journal of Medicine
Year: 2025
Volume: 392
Issue: 24
Pages: 2403-2412
Print publication date: 26/06/2025
Online publication date: 30/03/2025
Acceptance date: 02/04/2024
ISSN (print): 0028-4793
ISSN (electronic): 1533-4406
Publisher: Massachussetts Medical Society
URL: https://doi.org/10.1056/NEJMoa2415120
DOI: 10.1056/NEJMoa2415120
PubMed id: 40162661
Altmetrics provided by Altmetric
